Invasive meningococcal disease (IMD) research hub

A Phase 3b, open-label, multi-center study to assess the immune response and safety of the meningococcal group B vaccine rMenB+OMV NZ when administered to healthy participants aged 10 to 20 years old, who were primed during the first 2 years of life

This study is looking at how well a meningitis B vaccine, Bexsero, works and how safe it is in young people aged 10-20. Participants would have had their first meningitis B vaccinations as babies. We want to see if a booster dose helps protect them.